Updates

Ref: ADL/SE/2026-27/43 September 2, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Sub: Business Responsibility and Sustainability Report of the Company for Financial Year 2025-26 Ref: Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 In continuation to our intimation dated September 2, 2026 regarding the Annual Report for the Financial Year 2025-26 along with Notice of the 41st Annual General Meeting, and pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Business Responsibility and Sustainability Report for the Financial Year 2025-26. The said Report is also available on the website of the Company at https://www.aartidrugs.com/reports-fillings-annual-reports along with the Annual Report and Notice of the 41st Annual General Meeting of the Company. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Annual Report 2025-26 BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORTING SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Listed Entity L37060MH1984PLC055433 2. Name of the Listed Entity Aarti Drugs Limited 3. Year of incorporation 1984 4. Registered office address Plot No. N-198, M.I.D.C. Tarapur, Village – Pamtembhi, Taluka & Dist. Palghar- 401506 Maharashtra, India 5. Corporate address Ground Floor, Mahendra Industrial Estate, Plot No 109-D, Road No. 29, Sion (East), Mumbai – 400022, Maharashtra, India 6. E-mail investorrelations@aartidrugs.com 7. Telephone +9122-24019025 8. Website www.aartidrugs.com 9. Financial year for which reporting is being done April 01, 2025 to March 31, 2026 10. Name of the Stock Exchange(s) where shares are a. National Stock Exchange of India Limited listed b. BSE Limited 11. Paid-up Capital As on March 31, 2026 total paid up capital of the Company stood at ` 91,27,00,000 consisting of 91270000 Equity shares of ` 10/- each 12. Name and contact details (telephone, email a. Name - Rushikesh V. Deole address) of the person who may be contacted in b. Designation - Company Secretary case of any queries on the BRSR report c. Telephone Number - (022) 2401 9025 d. E-mail ID -investorrelations@aartidrugs.com 13. Reporting boundary - Are the disclosures under this Standalone basis (Business Responsibility initiatives of the report made on a standalone basis (i.e. only for parent Company are applicable to the subsidiary companies the entity) or on a consolidated basis (i.e. for the to the extent that they are material in relation to the business entity and all the entities which form a part of its activities of the subsidiaries). consolidated financial statements, taken together). 14. Name of assessment or assurance provider Not applicable, as BRSR Core Assurance is not mandatory 15. Type of assessment of assurance obtained for the Company. II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Manufacturing of Pharmaceuticals Manufacturing and Marketing of 100% Pharmaceuticals and Chemical products 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. No. Product/Service NIC Code % of total Turnover contributed 1 API 21001 89% 2 Speciality Chemicals 21001 8% 3 Intermediates & others 21001 3% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 13 2 15 International 0 0 0 Statutory Reports Aarti Drugs Limited BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORTING (CONTD.) 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 28 states and 8 union territories International (No. of Countries) Over 100 countries served across the six continents - Asia, North America, Europe, Africa, South America and Australia b. What is the contribution of exports as a percentage of the total turnover of the entity? The Company has a global presence with exports accounting for approximately 38% of its revenue. c. A brief on types of customers The Company serves a diverse global customer base, including pharmaceutical formulation companies, specialty chemical manufacturers, and dyes and pigments manufacturers across the globe. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): S. Particulars Total (A) Male Female No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 1028 873 84.92% 155 15.08% 2. Other than Permanent (E) 468 412 88.03% 56 11.97% 3. Total employees (D + E) 1496 1285 85.90% 211 14.10% WORKERS 4. Permanent (F) 327 326 99.69% 1 0.31% 5. Other than Permanent (G) 1008 971 96.33% 37 3.67% 6. Total workers (F + G) 1335 1297 97.15% 38 2.85% b. Differently abled Employees and workers: S. Particulars Total (A) Male Female No No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 2 1 50.00% 1 50.00% 2. Other than Permanent (E) 0 0 0.00% 0 0.00% 3. Total differently abled employees (D + E) 2 1 50.00% 1 50.00% DIFFERENTLY ABLED WORKERS 4. Permanent (F) 2 2 100% 0 0.00% 5. Other than permanent (G) 0 0 0.00% 0 0.00% 6. Total differently abled workers (F + G) 2 2 100% 0 0.00% 21. Participation/Inclusion/Representation of women Total (A) No. and percentage of Females No. (B) % (B / A) Board of Directors 12 1 8.33% Key Management Personnel 2 0 - Annual Report 2025-26 BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORTING (CONTD.) 22. Turnover rate for permanent employees and workers FY 2025-26 FY 2024-25 FY 2023-24 Male % Female % Total % Male % Female % Total % Male % Female % Total % Permanent Employees 20.23 9.79 18.71 9.25 10.26 9.38 8.64 12.00 9.08 Permanent Workers 6.27 0.00 6.25 4.99 0.00 4.98 2.46 0.00 2.46 V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures S. Name of the holding / subsidiary/ Indicate whether % of shares held by Does the entity indicated No. associate companies/ joint ventures holding/ listed entity at column A, participate in (A) Subsidiary/ the Business Responsibility Associate/ Joint initiatives of the listed Venture entity? (Yes/No) 1. Pinnacle Life Science Private Limited Subsidiary 100% Business Responsibility 2. Aarti Speciality Chemicals Limited Subsidiary 100% initiatives of the parent 3. Pinnacle Chile SpA Subsidiary 95% Company are applicable to 4. Pharma Go SpA Subsidiary 95% the subsidiary companies (through Pinnacle to the extent that they are Chile SpA) material in relation to the 5. Tripharma Chile SpA Subsidiary 95% business activities of the (through Pinnacle subsidiaries. Chile SpA) VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes (ii) Turnover (in `): 2,26,038.50 lakhs (iii) Networth (in `): 1,40,479.08 lakhs VII. Transparency and Disclosures Compliances 25. C omplaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Stakeholder Grievance Redressal Mechanism in Place FY 2025-26 FY 2024-25 group from (Yes/No) (If Yes, then provide web-link Number of Number of Remarks Number of Number of Remarks whom for grievance redress policy) complaints complaints complaints complaints complaint is filed during pending filed during pending received the year resolutio [Showing first 8,000 characters — download PDF for full document]